Hormone therapy and recurrence of venous thromboembolism among postmenopausal women

Menopause

Volumn 18, Issue 5, 2011, Pages 488-493

  Olié, Valérie ^a,b   Plu Bureau, Geneviève ^a,c,d   Conard, Jacqueline ^c,d   Horellou, Marie Hélène ^c,d   Canonico, Marianne ^a,b   Scarabin, Pierre Yves ^a,b  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hormone therapy; Recurrence; Transdermal estrogens; Venous thromboembolism

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DYDROGESTERONE; ESTROGEN; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; PROMEGESTONE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; RECURRENCE RISK; RECURRENT DISEASE; SUPERFICIAL THROMBOPHLEBITIS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; AGED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECURRENCE; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 79959952636     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181f9f7c3     Document Type: Article

References (23)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-699. (Pubitemid 46563566)
2. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-462. (Pubitemid 28082257)
3. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192-197. (Pubitemid 38952009)
4. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-1174. (Pubitemid 40417567)
5. Zhu T, Martinez I, Emmerich J. Venous thromboembolism risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310.
6. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. (Pubitemid 38489892)
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
8. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
9. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
10. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-774. (Pubitemid 30165237)
11. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768. (Pubitemid 30165236)
12. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica 2007;92:199-205.
13. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006;368:371-378. (Pubitemid 44108120)
14. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-2563.
15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361. (Pubitemid 40676757)
16. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (Clinical research ed) 2008;336:1227-1231. (Pubitemid 351809317)
17. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, doubleblind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemost 2000;84:961-967. (Pubitemid 32014029)
18. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. (Pubitemid 46294724)
19. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078. (Pubitemid 28016061)
20. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625. (Pubitemid 32293696)
21. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642-672.
22. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-1121. (Pubitemid 36713570)
23. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676. (Pubitemid 37108215)